Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes
These results provide the first comprehensive evidence in humans that imeglimin improves insulin secretion and insulin sensitivity in multiple tissues.
Authors
- Toshiki Kogai (ORCID: https://orcid.org/0009-0000-3126-3311)
- Hitoshi Naito (ORCID: https://orcid.org/0000-0001-7169-1169)
- Tsubasa Tajima
- Saori Kakehi (ORCID: https://orcid.org/0000-0002-1280-2882)
- Ryuzo Kawamori (ORCID: https://orcid.org/0000-0002-9686-9098)
- Yuya Nishida (ORCID: https://orcid.org/0000-0002-8396-423X)
- Naoaki Ito
- Hirotaka Watada
- Satoshi Kadowaki
- Hideyoshi Kaga
- Yoshifumi Tamura
Institutions
- Juntendo University (JP)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1111/dom.70449
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Kowa Company
- Boehringer Ingelheim Japan
- Novo Nordisk
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders
- Eli Lilly Japan
- Novo Nordisk Pharma